Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13516446 | 0.67 | — | — | |
| SCHEMBL6347666 | 0.67 | — | — | |
| SCHEMBL301287 | 0.67 | — | — | |
| SCHEMBL231837 | 0.65 | MAOA (0.37) | MAOAMAOB | |
| SCHEMBL8535446 | 0.64 | MAOA (0.39) | MAOAMAOB | |
| SCHEMBL1292005 | 0.64 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL29246 | 0.64 | — | — | |
| SCHEMBL240193 | 0.62 | MAOA (0.34) | MAOAMAOB | |
| SCHEMBL8115687 | 0.62 | MAOA (0.43) | MAOAMAOB | |
| SCHEMBL2347785 | 0.61 | MAOA (0.33) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 916 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | claimed |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| US-7897766-B2 | [3H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane, iodide; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, mild cognitive impairment, age-associated memory impairment | ABBOTT LABORATORIES (US) | 2011-03-01 | — | — | US | claimed |
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | claimed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | claimed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | claimed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | claimed |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-04-22 | — | — | US | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | claimed |
| US-5955481-A | Pyridine type thiazolidines | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | claimed |
| CN-1144526-A | Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents | NISSAN CHEMICAL IND LTD (JP) | 1997-03-05 | — | — | CN | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| US-5280009-A | Herbicide | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-18 | — | — | US | claimed |
| EP-0523533-A1 | Substituted pyrimidin derivatives and their use for combatting the growth of undesirable plants | BASF Aktiengesellschaft (DE) | 1993-01-20 | — | — | EP | claimed |
| EP-0090733-B1 | DISUBSTITUTED POLYMETHYLENE IMINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR (FR) | 1985-10-30 | — | — | EP | claimed |
| US-4514399-A | N-N'substituted polymethylene diamines | ADIR (FR) | 1985-04-30 | — | — | US | claimed |
| US-20240238427-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-12021194-B2 | Silicon-based energy storage devices with electrolyte containing a benzoyl peroxide based compound | ENEVATE CORPORATION (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2024-06-20 | — | — | US | disclosed |
| US-12015122-B2 | Silicon-based energy storage devices with carboxylic ether, carboxylic acid based salt, or acrylate electrolyte containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2024123791-A1 | FORMULATIONS FOR DUAL VEGF/IL-6 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11990585-B2 | Electrolyte formulations for optimal performance in Si-containing lithium ion batteries | ENEVATE CORPORATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-11978894-B2 | Silicon anodes with water-soluble maleic anhydride-, and/or maleic acid-containing polymers/copolymers, derivatives, and/or combinations (with or without additives) as binders | ENEVATE CORPORATION (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240125773-A1 | COMPOSITIONS AND METHODS FOR PREVENTING NON-SPECIFIC INTERACTIONS BETWEEN POLYMER DYES-ANTIBODY CONJUGATES | BECKMAN COULTER, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11961967-B2 | Silicon-based energy storage devices with phosphorus containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| US-11949072-B2 | Silicon-based energy storage devices with electrolyte containing cyanate based compounds | ENEVATE CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-11942599-B2 | Symmetrical or asymmetrical alkylsulfonyl imide or cyclic alkylene sulfonylimide salts as cathode additives, electrolyte additives, or SI anode additives for SI anode-based li-ion cells | ENEVATE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240084043-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4334395-A1 | UV-ABSORBING POLYMERS, COMPOSITIONS AND USES THEREOF | Beckman Coulter, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240079653-A1 | Electrolyte Formulations for Optimal Performance in Si-Containing Lithium Ion Batteries | ENEVATE CORPORATION | 2024-03-07 | — | — | US | disclosed |
| US-11923506-B2 | Silicon-based energy storage devices with ether containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| US-11923545-B2 | Crown ethers as additives for silicon-based Li-ion batteries | ENEVATE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024044327-A1 | DHNT MONOMERS AND POLYMER DYES WITH MODIFIED PHOTOPHYSICAL PROPERTIES | BECKMAN COULTER, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11912784-B2 | Methods of treating an eye disorder | KODIAK SCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323399-A1 | METHODS OF TREATING AN EYE DISORDER | Kodiak Sciences Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11903949-B2 | Fluoro beta-carboline compounds | OSSIFI THERAPEUTICS LLC (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240052092-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. | 2024-02-15 | — | — | US | disclosed |
| US-11901508-B2 | Silicon-based energy storage devices with functionalized linear sulfonate ester derivative compound containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-11894519-B2 | Silicon-based energy storage devices with linear carbonate containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-11888114-B2 | Silicon-based energy storage devices with fluorinated polymer containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| US-11876179-B2 | Silicon-based energy storage devices with electrolyte containing dimethoxyethane based compound | ENEVATE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11876180-B2 | Silicon-based energy storage devices with metal sulfide containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024010015-A1 | PYRIMIDINE DERIVATIVES | あすか製薬株式会社 | 2024-01-11 | — | — | WO | disclosed |
| US-20240011976-A1 | ADDITIVES FOR REDUCING NON-SPECIFIC INTERACTIONS BETWEEN FLUORESCENT POLYMER CONJUGATES AND CELLS IN A BIOLOGICAL SAMPLE | BECKMAN COULTER, INC. | 2024-01-11 | — | — | US | disclosed |
| WO-2024010772-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024007016-A2 | NOVEL FLUORESCENT DYES AND POLYMERS FROM DIHYDROPHENANTHRENE DERIVATIVES | BECKMAN COULTER, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11857645-B2 | Compositions of near IR closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands | Intuitive Surgical Operations, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117255832-A | Ultraviolet absorbing polymers, compositions and uses thereof | 贝克曼库尔特有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11848418-B2 | Single lithium-ion conductive polymer electrolytes for Si anode-based lithium-ion batteries | ENEVATE CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| US-11848419-B2 | Metal amide bases as electrolyte additives for Si anode-based Li-ion batteries | ENEVATE CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230399565-A1 | POLYMER DYES AND USES THEREOF | BECKMAN COULTER, INC. | 2023-12-14 | — | — | US | disclosed |
| EP-3915987-B1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOQC INC (CA) | 2023-12-13 | — | — | EP | disclosed |
| EP-4288776-A1 | COMPOSITIONS AND METHODS FOR PREVENTING NON-SPECIFIC INTERACTIONS BETWEEN POLYMER DYES-ANTIBODY CONJUGATES | Beckman Coulter, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11834551-B2 | Photoactive macromolecules and uses thereof | BECKMAN COULTER, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11837711-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230382983-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381329-A1 | Zwitterion Polymer-Drug Conjugates | UNIV UTAH RES FOUND (US) | 2023-11-30 | — | — | US | disclosed |
| US-11826721-B2 | Metal nanoparticle-deposited, nitrogen-doped carbon adsorbents for removal of sulfur impurities in fuels | CHEVRON U.S.A. INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11817578-B2 | Silicon-based energy storage devices with silyl amine compounds or derivatives of silyl amine containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| CN-117015711-A | Compositions and methods for preventing non-specific interactions between polymer dye-antibody conjugates | 贝克曼库尔特有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116997797-A | Additives for reducing non-specific interactions between fluorescent polymer conjugates and cells in biological samples | 贝克曼库尔特有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230346960-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-02 | — | — | US | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4244625-A1 | ADDITIVES FOR REDUCING NON-SPECIFIC INTERACTIONS BETWEEN FLUORESCENT POLYMER CONJUGATES AND CELLS IN A BIOLOGICAL SAMPLE | Beckman Coulter, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230279390-A1 | ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES | MPEG LA, L.L.C. | 2023-09-07 | — | — | US | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277545-A1 | COMPOSITIONS FOR LOCAL BONE FORMATION | OSSIFI THERAPEUTICS LLC | 2023-09-07 | — | — | US | disclosed |
| US-11749839-B2 | Silicon-based energy storage devices with electrolyte containing sulfonate or carboxylate salt based compounds | ENEVATE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023164678-A1 | AQUEOUS BASED POLYMERS FOR SILICON ANODES | ENEVATE CORPORATION (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230275230-A1 | AQUEOUS BASED POLYMERS FOR SILICON ANODES | ENEVATE CORPORATION | 2023-08-31 | — | — | US | disclosed |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023154822-A2 | METHODS OF PURIFYING A PRODUCT | KODIAK SCIENCES INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230250133-A1 | METHODS OF PURIFYING A PRODUCT | KODIAK SCIENCES GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| US-11721809-B2 | Silicate and organosilicon containing additives for silicon-based Li ion batteries | ENEVATE CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230201358-A1 | LINKER COMPOUNDS | MPEG LA, L.L.C. | 2023-06-29 | — | — | US | disclosed |
| US-20230203036-A1 | PYRROLO - DIPYRIDINE COMPOUNDS | OSSIFI THERAPEUTICS LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230180756-A1 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230178803-A1 | Silicon-Based Energy Storage Devices With Electrolyte Containing Sulfonate or Carboxylate Salt Based Compounds | ENEVATE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230173081-A1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023097250-A1 | COMPOSITIONS FOR LOCAL BONE FORMATION | OSSIFI-ML LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4183853-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | Beckman Coulter, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11655250-B2 | Pyrrolo-dipyridine compounds | OSTEOQC INC. (CA) | 2023-05-23 | — | — | US | disclosed |
| WO-2023086103-A1 | NOVEL FORMULATION FOR DRYING OF POLYMER DYE CONJUGATED ANTIBODIES | BECKMAN COULTER, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11652239-B2 | Silicon-based energy storage devices with electrolyte containing dihydrofuranone based compound | ENEVATE CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11646449-B2 | Cyclodextrin-based compounds and their derivatives for silicon-based li-ion batteries | ENEVATE CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230127931-A1 | SINGLE LITHIUM-ION CONDUCTIVE POLYMER ELECTROLYTES FOR SI ANODE-BASED LITHIUM-ION BATTERIES | ENEVATE CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230115890-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LINEAR CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-20230108463-A1 | PHOSPHORUS-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI ION BATTERIES | ENEVATE CORPORATION | 2023-04-06 | — | — | US | disclosed |
| US-20230103958-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND | ENEVATE CORPORATION | 2023-04-06 | — | — | US | disclosed |
| WO-2023056460-A1 | WATER-SOLUBLE TETRAHYDROPYRENE BASED FLUORESCENT POLYMERS | BECKMAN COULTER, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230099618-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230094087-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHAZENE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230095171-A1 | ORGANIC ACID ADDITIVES FOR SILICON-BASED LI ION BATTERIES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230101934-A1 | CYCLODEXTRIN-BASED COMPOUNDS AND THEIR DERIVATIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-20230096965-A1 | SILICATE AND ORGANOSILICON CONTAINING ADDITIVES FOR SILICON-BASED LI ION BATTERIES | ENEVATE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| EP-4153246-A1 | ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES | Mpeg LA, L.l.c. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11612663-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| EP-4146168-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146280-A1 | LINKER COMPOUNDS | Mpeg LA, L.l.c. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11605813-B2 | Silicon-based energy storage devices with functional terthiophene compound or thiophene oligomer compound containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-03-14 | — | — | US | disclosed |
| WO-2023033890-A1 | NITROGEN-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023033891-A1 | PHOSPHORUS-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
| CN-115737639-A | Compositions of near-IR closed-chain, thio-cyanine dyes and prostate-specific membrane antigen ligands | 直观外科手术操作公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11590235-B2 | Factor VIII zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11594733-B1 | Aqueous-based solid polymer suspensions in a polymer solution as a binder for Si dominant anodes | ENEVATE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| US-11584790-B2 | Complement factor D antagonist antibodies and conjugates thereof | KODIAK SCIENCES INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11569530-B2 | Silicon-based energy storage devices with functional thiophene compounds or derivatives of thiophene containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230029191-A1 | PRELITHIATION OF FREE-STANDING SILICON DOMINANT ANODE BATTERIES | ENEVATE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| WO-2023282999-A1 | PRELITHIATION OF FREE-STANDING SILICON DOMINANT ANODE BATTERIES | ENEVATE CORPORATION (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-11552334-B1 | Nitrogen-containing compounds as additives for silicon-based Li-ion batteries | ENEVATE CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230006252-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| EP-3889237-B1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11539077-B2 | Electrolyte additives containing one, two, or more triple-bonded moieties for silicon anode-based li-ion batteries | ENEVATE CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220393174-A1 | CROWN ETHERS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-12-08 | — | — | US | disclosed |
| US-11522223-B2 | Silicon-based energy storage devices with phosphazene containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-12-06 | — | — | US | disclosed |
| CN-108884036-B | Compositions of near-IR closed-chain, thio-cyanine dyes and prostate-specific membrane antigen ligands | 直观外科手术操作公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2022221395-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220294016-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2022-09-15 | — | — | US | disclosed |
| US-11431029-B2 | Silicon-based energy storage devices with functionalized linear sulfonate ester derivative compound containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| US-11431027-B1 | Single lithium-ion conductive polymer electrolytes for Si anode-based lithium-ion batteries | ENEVATE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022170084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING NON-SPECIFIC INTERACTIONS BETWEEN POLYMER DYES-ANTIBODY CONJUGATES | BECKMAN COULTER, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-3207128-B1 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-11398641-B2 | Silicon-based energy storage devices with silicon containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| CN-114786731-A | Methods of treating ocular disorders | 科达制药股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4029510-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Kodiak Sciences Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-109415623-B | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220213260-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220209227-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED CYCLIC COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORP (US) | 2022-06-30 | — | — | US | disclosed |
| US-11349153-B2 | Silicon-based energy storage devices with ether containing electrolyte additives | ENEVATE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11342588-B2 | Silicon-based energy storage devices with electrolyte containing dihydrofuranone based compound | ENEVATE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2022104147-A1 | ADDITIVES FOR REDUCING NON-SPECIFIC INTERACTIONS BETWEEN FLUORESCENT POLYMER CONJUGATES AND CELLS IN A BIOLOGICAL SAMPLE | BECKMAN COULTER, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022093717-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093716-A1 | SYMMETRICAL OR ASYMMETRICAL ALKYLSULFONYL IMIDE OR CYCLIC ALKYLENE SULFONYLIMIDE SALTS AS CATHODE ADDITIVES, ELECTROLYTE ADDITIVES, OR SI ANODE ADDITIVES FOR SI ANODE-BASED LI-ION CELLS | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093719-A1 | METAL AMIDE BASES AS ELECTROLYTE ADDITIVES FOR SI ANODE-BASED LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093792-A1 | ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093797-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220140392-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-20220131148-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20220131195-A1 | ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20220131194-A1 | METAL AMIDE BASES AS ELECTROLYTE ADDITIVES FOR SI ANODE-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20220131193-A1 | SYMMETRICAL OR ASYMMETRICAL ALKYLSULFONYL IMIDE OR CYCLIC ALKYLENE SULFONYLIMIDE SALTS AS CATHODE ADDITIVES, ELECTROLYTE ADDITIVES, OR SI ANODE ADDITIVES FOR SI ANODE-BASED LI-ION CELLS | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20220102713-A1 | AQUEOUS BASED POLYMERS FOR SILICON DOMINANT ANODES | ENEVATE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| CN-109196004-B | Engineered scaffold for vascularized tissue repair | 加利福尼亚大学董事会 | 2022-03-18 | — | — | CN | disclosed |
| US-20220080382-A1 | METAL NANOPARTICLE-DEPOSITED, NITROGEN-DOPED CARBON ADSORBENTS FOR REMOVAL OF SULFUR IMPURITIES IN FUELS | CHEVRON U.S.A. INC. | 2022-03-17 | — | — | US | disclosed |
| CN-108137513-B | Pyrimidine derivatives | ASKA 制药株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-20220052380-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC ORGANOSILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2022-02-17 | — | — | US | disclosed |
| US-11246961-B2 | Engineered scaffolds for vascularized tissue repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220024922-A1 | PYRROLO - DIPYRIDINE COMPOUNDS | OSSIFI THERAPEUTICS LLC | 2022-01-27 | — | — | US | disclosed |
| US-20220013768-A1 | SILICON ANODES WITH WATER-SOLUBLE MALEIC ANHYDRIDE-, AND/OR MALEIC ACID-CONTAINING POLYMERS/COPOLYMERS, DERIVATIVES, AND/OR COMBINATIONS (WITH OR WITHOUT ADDITIVES) AS BINDERS | ENEVATE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| WO-2022010676-A1 | SILICON ANODES WITH WATER-SOLUBLE MALEIC ANHYDRIDE-. AND/OR MALEIC ACID-CONTAINING POLYMERS/COPOLYMERS, DERIVATIVES, AND/OR COMBINATIONS (WITH OR WITHOUT ADDITIVES) AS BINDERS | ENEVATE CORPORATION (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3549963-B1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210402015-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11208527-B2 | Photoactive macromolecules and uses thereof | BECKMAN COULTER, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | disclosed |
| CN-113801297-A | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-113801296-A | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2021-12-17 | — | — | CN | disclosed |
| EP-3426700-B1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | UNIV CALIFORNIA (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3915987-A1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | Osteoqc Inc. (CA) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021236689-A1 | ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES | MPEG LA, L.L.C. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021226404-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226454-A1 | LINKER COMPOUNDS | MPEG LA, L.L.C. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210344047-A1 | Silicon-Based Energy Storage Devices With Fluorinated Polymer Containing Electrolyte Additives | ENEVATE CORPORATION | 2021-11-04 | — | — | US | disclosed |
| US-11165099-B2 | Silicon-based energy storage devices with cyclic organosilicon containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-11155610-B2 | Dual PDGF/VEGF antagonists | KODIAK SCIENCES INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210324063-A1 | ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3372589-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-3889237-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | Beckman Coulter, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113416187-A | Alkylamine peganine derivatives for promoting bone growth | 奥斯特克有限公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-3874556-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHAZENE CONTAINING ELECTROLYTE ADDITIVES | Enevate Corporation (US) | 2021-09-08 | — | — | EP | disclosed |
| US-11114660-B1 | Silicon anodes with water-soluble maleic anhydride-, and/or maleic acid-containing polymers/copolymers, derivatives, and/or combinations (with or without additives) as binders | ENEVATE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3453711-B1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210249689-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING CYANATE BASED COMPOUNDS | ENEVATE CORPORATION | 2021-08-12 | — | — | US | disclosed |
| WO-2021158366-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING CYANATE BASED COMPOUNDS | ENEVATE CORPORATION (US) | 2021-08-12 | — | — | WO | disclosed |
| US-11075408-B2 | Silicon-based energy storage devices with fluorinated polymer containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071771-B2 | Butyrylcholinesterase zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2021-07-27 | — | — | US | disclosed |
| CN-113166058-A | Fluoro beta-carboline compounds | 奥斯特克有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210226251-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING CROWN ETHER BASED COMPOUNDS | ENEVATE CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-11066465-B2 | Antibodies and conjugates thereof | KODIAK SCIENCES INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-105611920-B | Preparation of hydroxy-diphenylmethane derivatives | 泰拉科斯萨普有限责任公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210218059-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| US-20210194056-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING SULFONATE OR CARBOXYLATE SALT BASED COMPOUNDS | ENEVATE CORPORATION | 2021-06-24 | — | — | US | disclosed |
| EP-3836923-A1 | PYRROLO - DIPYRIDINE COMPOUNDS | Osteoqc Inc. (CA) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837241-A1 | FLUORO ß-CARBOLINE COMPOUNDS | Osteoqc Inc. (CA) | 2021-06-23 | — | — | EP | disclosed |
| CN-112996506-A | Pyrrolodipyridine compounds | 奥斯特克有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210184258-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING DIHYDROFURANONE BASED COMPOUND | ENEVATE CORPORATION | 2021-06-17 | — | — | US | disclosed |
| CN-112970141-A | Silicon-based energy storage device with electrolyte additive containing phosphazene | 新强能电池公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-105120863-B | Alkylamine peganine derivatives for promoting bone growth | 奥斯特克有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20210167423-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND | ENEVATE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-20210167361-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-20210154332-A1 | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands | Intuitive Surgical Operations, Inc. | 2021-05-27 | — | — | US | disclosed |
| EP-3823630-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210135288-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH WITH METAL SULFIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-05-06 | — | — | US | disclosed |
| EP-2968284-B1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOQC INC (CA) | 2021-04-21 | — | — | EP | disclosed |
| CN-112672747-A | Peptides for activating cell signalling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2021-04-16 | — | — | CN | disclosed |
| WO-2021072265-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107999-A1 | METHODS OF TREATING AN EYE DISORDER | KODIAK SCIENCES INC. | 2021-04-15 | — | — | US | disclosed |
| EP-3443049-B1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10978739-B2 | Silicon-based energy storage devices with carboxylic ether, carboxylic acid based salt, or acrylate electrolyte containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210098827-A1 | Silicon-Based Energy Storage Devices With Electrolyte Containing Dimethoxyethane Based Compound | ENEVATE CORPORATION | 2021-04-01 | — | — | US | disclosed |
| US-20210093728-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-01 | — | — | US | disclosed |
| US-10957898-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-03-23 | — | — | US | disclosed |
| US-10947236-B2 | Pyrrolo-dipyridine compounds | OSTEOQC INC. (CA) | 2021-03-16 | — | — | US | disclosed |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10888629-B2 | Compositions of near IR closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands | Intuitive Surgical Operations, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| CN-112203679-A | IL-6 antibodies and fusion constructs and conjugates thereof | 科达制药股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3760639-A1 | ZWITTERIONIC POLYMER CONJUGATES | Kodiak Sciences Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3758737-A1 | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200388882-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388879-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388876-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH SILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388837-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH SILYL AMINE COMPOUNDS OR DERIVATIVES OF SILYL AMINE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388885-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LIPO2F2 SALT-CONTAINING ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388881-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONAL THIOPHENE COMPOUNDS OR DERIVATIVES OF THIOPHENE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200388836-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONAL TERTHIOPHENE COMPOUND OR THIOPHENE OLIGOMER COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200369723-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200373620-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORP (US) | 2020-11-26 | — | — | US | disclosed |
| US-10811727-B2 | Silicon-based energy storage devices with ether containing electrolyte additives | ENEVATE CORPORATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200261590-A1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2020-08-20 | — | — | US | disclosed |
| EP-3041513-B1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10710967-B2 | Pyrimidine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-10702608-B2 | Factor VIII zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200203711-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200203764-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC ORGANOSILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| WO-2020132072-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC ORGANOSILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132057-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200171179-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172538-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2020-06-04 | — | — | US | disclosed |
| EP-3659591-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | Kodiak Sciences Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200144672-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHORUS CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-05-07 | — | — | US | disclosed |
| US-20200136185-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH PHOSPHAZENE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-05 | — | — | US | disclosed |
| US-20200055853-A1 | PYRROLO - DIPYRIDINE COMPOUNDS | OSSIFI THERAPEUTICS LLC | 2020-02-20 | — | — | US | disclosed |
| WO-2020037004-A1 | PYRROLO - DIPYRIDINE COMPOUNDS | OSTEOQC INC. (CA) | 2020-02-20 | — | — | WO | disclosed |
| US-20200054645-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | OSSIFI THERAPEUTICS LLC | 2020-02-20 | — | — | US | disclosed |
| WO-2020037001-A1 | FLUORO β-CARBOLINE COMPOUNDS | OSTEOQC INC. (CA) | 2020-02-20 | — | — | WO | disclosed |
| EP-3610010-A2 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3254678-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20200030461-A1 | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands | Intuitive Surgical Operations, Inc. | 2020-01-30 | — | — | US | disclosed |
| WO-2020018941-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-23 | — | — | WO | disclosed |
| EP-3055281-B1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | THERACOS SUB LLC (US) | 2020-01-08 | — | — | EP | disclosed |
| WO-2019195780-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-3549963-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Kodiak Sciences Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190270806-A1 | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2019-09-05 | — | — | US | disclosed |
| US-20190262798-A1 | METAL NANOPARTICLE-DEPOSITED, NITROGEN-DOPED CARBON ADSORBENTS FOR REMOVAL OF SULFUR IMPURITIES IN FUELS | CHEVRON U.S.A. INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190255155-A1 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS, LLC | 2019-08-22 | — | — | US | disclosed |
| US-20190247539-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-15 | — | — | US | disclosed |
| US-10363290-B2 | Butyrylcholinesterase zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2019-07-30 | — | — | US | disclosed |
| CN-102946877-B | Application of mastoid and its separated compound in preparing medicine for treating nerve diseases | 香港科技大学 | 2019-07-05 | — | — | CN | disclosed |
| EP-2558538-B1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190190070-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-20 | — | — | US | disclosed |
| US-20190190069-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LINEAR CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-20 | — | — | US | disclosed |
| US-20190181441-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED CYCLIC COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| US-20190181501-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CYCLIC CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| US-20190181502-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| WO-2019113532-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED CYCLIC COMPOUND CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113528-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113526-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED POLYMER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113530-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ETHER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113518-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LINEAR CARBONATE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190181500-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED POLYMER CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-13 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190144601-A1 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3453711-A1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | The Regents of the University of California (US) | 2019-03-13 | — | — | EP | disclosed |
| CN-109415623-A | Photosensitive macromolecules and uses thereof | 拜克门寇尔特公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3443049-A2 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | Beckman Coulter Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3426700-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | The Regents of The University of California (US) | 2019-01-16 | — | — | EP | disclosed |
| CN-109196004-A | Engineered scaffold for vascularized tissue repair | 加利福尼亚大学董事会 | 2019-01-11 | — | — | CN | disclosed |
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180334496-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2018-11-22 | — | — | US | disclosed |
| EP-3397276-A1 | ANTIBODIES AND CONJUGATES THEREOF | Kodiak Sciences Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| CN-108712911-A | Antibody and its conjugate | 科达制药股份有限公司 | 2018-10-26 | — | — | CN | disclosed |
| WO-2018191548-A2 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| US-10093616-B2 | Preparation of hydroxy-benzylbenzene derivatives | THERACOS SUB, LLC (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
| EP-3372589-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2018-09-12 | — | — | EP | disclosed |
| US-10071101-B2 | Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180244762-A1 | DUAL PDGF/VEGF ANTAGONISTS | KODIAK SCIENCES INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-2753626-B1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180201989-A1 | OXIDANT AND USE THEREOF | THE UNIVERSITY OF TOKYO (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9840553-B2 | Dual PDGF/VEGF antagonists | KODIAK SCIENCES INC. (US) | 2017-12-12 | — | — | US | disclosed |
| CN-107428824-A | PDGF/VEGF dual antagonists | 科达制药 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017184383-A1 | COMPOSITIONS OF NEAR IR CLOSED CHAIN, SULFO-CYANINE DYES AND PROSTATE SPECIFIC MEMBRANE ANTIGEN LIGANDS | Intuitive Surgical Operations, Inc. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017180998-A2 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF | BECKMAN COULTER, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170296679-A1 | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands | Intuitive Surgical Operations, Inc. | 2017-10-19 | — | — | US | disclosed |
| CN-107208076-A | Butyrylcholine esterase amphoteric ion polymer conjugate | 科达制药 | 2017-09-26 | — | — | CN | disclosed |
| WO-2017156427-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-14 | — | — | WO | disclosed |
| US-9751821-B1 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-3207128-A2 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | Kodiak Sciences Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2512462-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170233321-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9725478-B2 | Process for the preparation of benzylbenzene SGLT2 inhibitors | THERACOS SUB, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2017117464-A1 | ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170190766-A1 | ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | US | disclosed |
| US-9676692-B2 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20170143841-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143727-A1 | USE OF CINNABARINIC ACID AS A MODULATOR OF IMMUNE RESPONSE IN AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-25 | — | — | US | disclosed |
| EP-3161000-A2 | DUAL PDGF/VEGF ANTAGONISTS | Kodiak Sciences Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| EP-2792675-B1 | COMPOUND AND ASYMMETRIC SYNTHESIS REACTION | MICROBIAL CHEM RES FOUND (JP) | 2017-04-12 | — | — | EP | disclosed |
| CN-106432557-A | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | 科迪亚科学企业公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9561256-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170007710-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2017-01-12 | — | — | US | disclosed |
| US-9540365-B2 | Compounds for bone growth | OSTEOQC INC. (CA) | 2017-01-10 | — | — | US | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20160355471-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | THERACOSBIO, LLC | 2016-12-08 | — | — | US | disclosed |
| EP-2218716-B1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| CN-106075466-A | Multi-functional amphoteric ion polymer conjugate | 科迪亚科学企业公司 | 2016-11-09 | — | — | CN | disclosed |
| US-9486457-B2 | Use of cinnabarinic acid as a modulator of immune responses in autoimmune disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-08 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464043-B2 | Preparation of hydroxy-benzylbenzene derivatives | THERACOS SUB, LLC (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160257651-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2016-09-08 | — | — | US | disclosed |
| EP-3055281-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | Theracos Sub, LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9403781-B2 | Crystalline 1H-1,2,3-triazol-5-ylidenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160207952-A1 | PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS | THERACOSBIO, LLC | 2016-07-21 | — | — | US | disclosed |
| US-20160199501-A1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2016-07-14 | — | — | US | disclosed |
| EP-3041513-A2 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | Kodiak Sciences Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160184445-A1 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS, LLC | 2016-06-30 | — | — | US | disclosed |
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| WO-2016061562-A2 | BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| EP-2221306-B1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL IND LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-103998439-B | compound and asymmetric synthesis reaction | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2016-03-23 | — | — | CN | disclosed |
| US-20160074461-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-17 | — | — | US | disclosed |
| EP-2987787-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | Juntendo Educational Foundation (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20160017000-A1 | RGD-CONTAINING CYCLIC PEPTIDES | UNIV CALIFORNIA (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2968284-A2 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | Osteoqc Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376271-A1 | DUAL PDGF/VEGF ANTAGONISTS | OLIGASIS, LLC (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2015200905-A2 | DUAL PDGF/VEGF ANTAGONISTS | OLIGASIS, LLC (US) | 2015-12-30 | — | — | WO | disclosed |
| CN-105120863-A | Alkylamine peganine derivatives for promoting bone growth | OSTEOQC INC | 2015-12-02 | — | — | CN | disclosed |
| US-9193751-B2 | Process for the preparation of benzylbenzene SGLT2 inhibitors | THERACOS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9187498-B2 | Compound and asymmetric synthesis reaction | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9162939-B2 | Carbon nanohoops and methods of making | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-20 | — | — | US | disclosed |
| US-9150608-B2 | Neuro-protective compounds and their use | Biotechnology Research Corp. Ltd. (CN) | 2015-10-06 | — | — | US | disclosed |
| US-9126995-B2 | Method for catalytic asymmetric synthesis of optically active isoxazoline compound and optically active isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9119884-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-01 | — | — | US | disclosed |
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20150210634-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | THERACOSBIO, LLC | 2015-07-30 | — | — | US | disclosed |
| US-9073974-B2 | RGD-containing cyclic peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150183807-A1 | Compound and Asymmetric Synthesis Reaction | MICROBIAL CHEM RES FOUND (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20150152022-A1 | CARBON NANOHOOPS AND METHODS OF MAKING | ENERGY, UNITED STATES DEPARTMENT OF | 2015-06-04 | — | — | US | disclosed |
| US-20150119576-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2015051484-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | THERACOS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND (DE) | 2015-04-16 | — | — | US | disclosed |
| WO-2015051597-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | THERACOS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8987538-B2 | Carbon nanohoops and methods of making | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8981123-B2 | Compound and asymmetric synthesis reaction | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2015-03-17 | — | — | US | disclosed |
| WO-2015035342-A2 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS LLC (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2836500-A1 | PROCESS FOR PREPARATION OF BENZYLBENZENE SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS | Theracos, Inc. (US) | 2015-02-18 | — | — | EP | disclosed |
| US-8952175-B2 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-104334568-A | Preparation method of benzylbenzene sodium-dependent glucose cotransporter 2(SGLT2) inhibitor | THERACOS INC | 2015-02-04 | — | — | CN | disclosed |
| CN-102405221-B | Process for production of 2-azaadamantane compound from bicyclocarbamate compound | NISSAN CHEMICAL IND LTD | 2015-01-21 | — | — | CN | disclosed |
| US-20150004128-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS, LLC (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140350261-A1 | METHOD FOR CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE ISOXAZOLINE COMPOUND, AND OPTICALLY ACTIVE ISOXAZOLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8895749-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2792675-A1 | COMPOUND AND ASYMMETRIC SYNTHESIS REACTION | Microbial Chemistry Research Foundation (JP) | 2014-10-22 | — | — | EP | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296539-A1 | Compound and Asymmetric Synthesis Reaction | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2014-10-02 | — | — | US | disclosed |
| WO-2014153203-A2 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSSIFI INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288068-A1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSSIFI INC. (US) | 2014-09-25 | — | — | US | disclosed |
| CN-102448949-B | Heterocyclic compound and hematopoietic stem cell amplifier | NISSAN CHEMICAL IND LTD | 2014-09-03 | — | — | CN | disclosed |
| CN-103998439-A | Compound and asymmetric synthesis reaction | MICROBIAL CHEM RES FOUND | 2014-08-20 | — | — | CN | disclosed |
| US-20140227780-A1 | METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2765187-A1 | METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS | Nissan Chemical Industries, Ltd. (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-8765432-B2 | Targeted drug phosphorylcholine polymer conjugates | OLIGASIS, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140113012-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | disclosed |
| US-8669367-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8664396-B2 | Photoluminescent metal complexes for protein staining | BIO-RAD LABORATORIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664277-B2 | Compounds and methods for PKCθ inhibition | COMPLEGEN PARTNERS, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20140024776-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140023653-A1 | BOLDINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. | 2014-01-23 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| CN-103492489-A | High molecular weight zwitterionic polymers | OLIGASIS | 2014-01-01 | — | — | CN | disclosed |
| US-8598154-B2 | Pyridyl-amine fused azadecalin modulators | CORCEPT THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130315965-A1 | HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOQC INC. (CA) | 2013-11-28 | — | — | US | disclosed |
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE INC. (US) | 2013-11-21 | — | — | US | disclosed |
| CN-103402516-A | Compounds useful as antiviral agents, compositions, and methods of use | FUZIANS BIOMEDICALS INC | 2013-11-20 | — | — | CN | disclosed |
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580773-B2 | Small-molecule inhibitors of the androgen receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-12 | — | — | US | disclosed |
| US-8575146-B2 | Pharmaceutical uses of staurosporine derivatives | NOVARTIS AG (CH) | 2013-11-05 | — | — | US | disclosed |
| US-20130289018-A1 | New Use of Staurosporine Derivatives | COUTRE STEVEN (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2013152476-A1 | PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS | THERACOS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013152654-A1 | PROCESS FOR PREPARATION OF BENZYLBENZENE SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS | THERACOS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130267694-A1 | PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS | THERACOS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20130245327-A1 | CARBON NANOHOOPS AND METHODS OF MAKING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130225687-A1 | COMPOUNDS AND METHODS FOR PKC THETA INHIBITION | COMPLEGEN PARTNERS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8513274-B2 | Ellipticine compounds for treating obesity | Etzem, Inc. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-01 | — | — | US | disclosed |
| CN-102190661-B | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2013-07-31 | — | — | CN | disclosed |
| US-20130172270-A1 | RGD-CONTAINING CYCLIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2609097-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | Corcept Therapeutics, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8460642-B2 | Boldline compounds for promoting bone growth | OssiFi, Inc. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461403-B2 | Carbon nanohoops and methods of making | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-11 | — | — | US | disclosed |
| US-8445479-B2 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8445686-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8436025-B2 | Compounds and methods for PKC theta inhibition | CompleGen Partners, Inc. (US) | 2013-05-07 | — | — | US | disclosed |
| CN-103080108-A | Pyridyl-amine fused azadecalin modulators | CORCEPT THERAPEUTICS INC | 2013-05-01 | — | — | CN | disclosed |
| WO-2013059137-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130096095-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-18 | — | — | US | disclosed |
| CN-101523292-B | Method for manufacturing semiconductor device using quadruple-layer laminate | NISSAN CHEMICAL IND LTD | 2013-04-10 | — | — | CN | disclosed |
| US-20130079293-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2013-03-28 | — | — | US | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| WO-2013032527-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-07 | — | — | WO | disclosed |
| CN-102946877-A | Neuroprotective effect of mastoid fruits (Adelostemma gracilimum) and isolated compounds thereof | BIOTECHNOLOGY RES CORP LTD | 2013-02-27 | — | — | CN | disclosed |
| US-20130045522-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2558538-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | Oligasis (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035333-A1 | USE OF CINNABARINIC ACID AS A MODULATOR OF IMMUNE RESPONSES IN AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130034517-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS (US) | 2013-02-07 | — | — | US | disclosed |
| CN-101223154-B | Thiophene compounds and thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD | 2013-01-23 | — | — | CN | disclosed |
| EP-2085823-B1 | METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE USING QUADRUPLE-LAYER LAMINATE | NISSAN CHEMICAL IND LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101861315-B | Method for producing 2-azaadamantane | NISSAN CHEMICAL IND LTD | 2013-01-16 | — | — | CN | disclosed |
| US-8354538-B2 | Small-molecule inhibitors of the androgen receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-15 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| CN-102816165-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB | 2012-12-12 | — | — | CN | disclosed |
| US-8329909-B2 | Method for producing 2-azaadamantane compound from bicyclocarbamate compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | TOHOKU TECHNO ARCH CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| CN-102811713-A | Multifunctional Zwitterionic Polymer Conjugates | OLIGASIS | 2012-12-05 | — | — | CN | disclosed |
| US-20120301509-A1 | BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2512462-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | Oligasis (US) | 2012-10-24 | — | — | EP | disclosed |
| CN-1934116-B | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD | 2012-10-10 | — | — | CN | disclosed |
| US-20120252785-A1 | STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| WO-2012129562-A2 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | WO | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120231010-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-2217608-B1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | BIO RAD LABORATORIES (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220565-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| CN-101437827-B | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL IND LTD | 2012-08-29 | — | — | CN | disclosed |
| EP-2476681-A2 | Amino-aza-adamantane derivatives and methods of use | Abbott Laboratories (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8222244-B2 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| CN-1980910-B | Benzopyran compound for treating arrhythmia | NISSAN CHEMICAL IND LTD | 2012-06-13 | — | — | CN | disclosed |
| US-8198292-B2 | Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof | OSTEOGENEX, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| CN-101429200-B | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2012-05-30 | — | — | CN | disclosed |
| US-8188065-B2 | Boldine compounds for promoting bone growth | OSTEOGENEX INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| CN-102448949-A | Heterocyclic compound and hematopoietic stem cell amplifier | NISSAN CHEMICAL IND LTD | 2012-05-09 | — | — | CN | disclosed |
| CN-101072766-B | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD | 2012-05-02 | — | — | CN | disclosed |
| CN-101849953-B | Inflammatory cytokine release inhibitor | INST MED MOLECULAR DESIGN INC | 2012-04-25 | — | — | CN | disclosed |
| EP-1844766-B1 | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012045194-A1 | BENZODIAZEPINONES AS FAK INHIBITORS FOR TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2439204-A1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | Nissan Chemical Industries, Ltd. (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-102405221-A | Process for production of 2-azaadamantane compound from bicyclocarbamate compound | NISSAN CHEMICAL IND LTD | 2012-04-04 | — | — | CN | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| WO-2012031228-A2 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120053348-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027702-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-2423212-A1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8080575-B2 | Gamma-lactam compounds for promoting bone growth | OSTEOGENEX INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110301192-A1 | Inhibitors of Cyclin Kinase Inhibitor p21 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011139704-A2 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | WO | disclosed |
| US-8053453-B2 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| CN-101386596-B | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD | 2011-10-26 | — | — | CN | disclosed |
| WO-2011130694-A2 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| WO-2011114220-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2011-09-22 | — | — | WO | disclosed |
| CN-102190661-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2011-09-21 | — | — | CN | disclosed |
| US-20110224253-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224194-A1 | Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-09-15 | — | — | US | disclosed |
| EP-2364318-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | Bio-Rad Laboratories, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| CN-1582150-B | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG | 2011-09-07 | — | — | CN | disclosed |
| WO-2011106408-A1 | THE USE OF CINNABARINIC ACID AS A MODULATOR OF IMMUNE RESPONSE IN AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-01 | — | — | WO | disclosed |
| CN-101076519-B | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL IND LTD | 2011-07-20 | — | — | CN | disclosed |
| US-20110166390-A1 | CARBON NANOHOOPS AND METHODS OF MAKING | LAWRENCE BERKELEY NATIONAL LABORATORY (US) | 2011-07-07 | — | — | US | disclosed |
| US-7973032-B2 | Staurosporine derivatives for use in alveolar rhabdomyosarcoma | UNIVERSITY OF ZURICH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-7973031-B2 | Leukemia therapy ;myelodyspastic syndrome | NOVARTIS AG (CH) | 2011-07-05 | — | — | US | disclosed |
| WO-2011079015-A1 | RGD-CONTAINING CYCLIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-30 | — | — | WO | disclosed |
| US-7968542-B2 | Thiophene compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| WO-2011075185-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075736-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | OLIGASIS (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2320896-A2 | VINPOCETINE AND EBURNAMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | Osteogenex Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20110092496-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2305265-A1 | Combinations comprising staurosporines | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7897766-B2 | [3H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane, iodide; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, mild cognitive impairment, age-associated memory impairment | ABBOTT LABORATORIES (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2011017219-A1 | IMIDAZOQUINOXALINONES AND ANTI-TUMOR TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-2276345-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | The Regents of the University of California (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100310537-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100310535-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-7842620-B2 | Method for manufacturing semiconductor device using quadruple-layer laminate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20100298559-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| CN-101889007-A | Method for expansion of hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL IND LTD | 2010-11-17 | — | — | CN | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| CN-101861315-A | The manufacture method of 2-aza-adamantane class | NISSAN CHEMICAL IND LTD | 2010-10-13 | — | — | CN | disclosed |
| CN-101849953-A | Inflammatory cytokine release inhibitor | INST MED MOLECULAR DESIGN INC | 2010-10-06 | — | — | CN | disclosed |
| US-20100249171-A1 | ELLIPTICINE COMPOUNDS FOR TREATING OBESITY | OSTEOGENEX INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2233468-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233561-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010107704-A2 | ELLIPTICINE COMPOUNDS FOR TREATING OBESITY | OSTEOGENEX INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| CN-101842359-A | Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors | NISSAN CHEMICAL IND LTD | 2010-09-22 | — | — | CN | disclosed |
| CN-1658872-B | Antiallergic agent | INST MED MOLECULAR DESIGN INC | 2010-09-22 | — | — | CN | disclosed |
| EP-2228434-A1 | AMPLIFICATION METHOD FOR HEMATOPOIETIC STEM CELLS WITH HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2221306-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | Nissan Chemical Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7781488-B2 | convergent assembly of a plurality of pairs of oligopeptides; stable C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester; allows a single precursor to participate in a succession of chemical ligation reactions | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| EP-2218716-A1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| EP-2217608-A1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | Bio-Rad Laboratories, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-20100184820-A1 | COMBINATIONS COMPRISING STAUROSPORINES | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| WO-2010080756-A2 | HARMINE DERIVATIVES FOR REDUCING BODY WEIGHT | OSTEOGENEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100173931-A1 | HARMINE DERIVATIVES FOR REDUCING BODY WEIGHT | OSTEOGENEX INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2203429-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100144046-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | BIO-RAD LABORATORIES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010065514-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | BIO-RAD LABORATORIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100143441-A1 | NORTRIPTYLINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| EP-2193119-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | Abbott GmbH & Co. KG (DE) | 2010-06-09 | — | — | EP | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| US-20100137612-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND FOR PRODUCTION OF 2- PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-7723322-B2 | Fluoride carrier for positron emission tomography | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100120869-A1 | COMPOUNDS AND METHODS FOR PKC THETA INHIBITION | COMPLEGEN, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1373262-B1 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | NOVARTIS AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| CN-101703509-A | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG | 2010-05-12 | — | — | CN | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| CN-1658855-B | O-substituted hydroxyaryl derivatives | INST MED MOLECULAR DESIGN INC | 2010-04-28 | — | — | CN | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20100092559-A1 | BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039668-A2 | INHIBITORS OF CYCLIN KINASE INHIBITOR P21 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039920-A2 | BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-2172462-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND, AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| WO-2010036567-A2 | HARMINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010033655-A1 | COMPOUNDS AND METHODS FOR PKC THETA INHIBITION | COMPLEGEN, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100074939-A1 | HARMINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010025135-A2 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100047314-A1 | FOLINIC ACID DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2010022201-A2 | FOLINIC ACID DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1529056-B1 | POST-CLEAVAGE SULFUR DEPROTECTION FOR CONVERGENT PROTEIN SYNTHESIS BY CHEMICAL LIGATION | AMYLIN PHARMACEUTICALS INC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010019549-A2 | INDOPROFEN DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100040628-A1 | INDOPROFEN DERIVATIVES FOR PROMOTING BONE GROWTH | OsteoGeneX, Inc (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2010011599-A2 | PIMETHIXENE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021524-A1 | PIMETHIXENE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022089-A1 | Method for manufacturing semiconductor device using quadruple-layer laminate | NISSIAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| CN-101636392-A | Process for production of optically active epoxy compound | NISSAN CHEMICAL IND LTD | 2010-01-27 | — | — | CN | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20100003324-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002835-A2 | VINPOCETINE AND EBURNAMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009148874-A2 | GAMMA-LACTAM COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090297606-A1 | GAMMA-LACTAM COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20090286770-A1 | Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2009-11-19 | — | — | US | disclosed |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| WO-2009132307-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7595415-B2 | α-Substituted vinyltin compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| CN-100536850-C | Combinations comprising staurosporines | NOVARTIS AG (CH) | 2009-09-09 | — | — | CN | disclosed |
| CN-101523292-A | Method for manufacturing semiconductor device using quadruple-layer laminate | NISSAN CHEMICAL IND LTD (JP) | 2009-09-02 | — | — | CN | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| CN-101505760-A | Combinations comprising staurosprorines | NOVARTIS AG (CH) | 2009-08-12 | — | — | CN | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085823-A1 | METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE USING QUADRUPLE-LAYER LAMINATE | Nissan Chemical Industries, Ltd. (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| CN-100506221-C | Cancer therapeutic agent | INST MED MOLECULAR DESIGN INC (JP) | 2009-07-01 | — | — | CN | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2009070533-A1 | METHODS OF INHIBITING STEROYL COA DESATURASE | COMPLEGEN, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009067603-A1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | BIO-RAD LABORATORIES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| CN-100490793-C | Remedies for neurodegenerative diseases | INST MED MOLECULAR DESIGN INC (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-20090131640-A1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | BIO-RAD LABORATORIES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| CN-101437827-A | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL IND LTD (JP) | 2009-05-20 | — | — | CN | disclosed |
| US-20090124806-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID FROM PRIMARY ALCOHOL | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| CN-101429200-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-05-07 | — | — | US | disclosed |
| WO-2009057827-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| CN-100478331-C | Inhibitors of cathepsin s | IRM LLC (BM) | 2009-04-15 | — | — | CN | disclosed |
| EP-2037933-A2 | COMBINATIONS COMPRISING STAUROSPRORINES | Novartis Ag (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-7507755-B2 | Inhibitors of cathepsin s | IRM LLC (BM) | 2009-03-24 | — | — | US | disclosed |
| CN-101386596-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2009-03-18 | — | — | CN | disclosed |
| US-7501408-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2009-03-10 | — | — | US | disclosed |
| WO-2009027392-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBOTT GMBH & CO. KG (DE) | 2009-03-05 | — | — | WO | disclosed |
| CN-100464742-C | NF-kB activation inhibitor | INST MED MOLECULAR DESIGN INC (JP) | 2009-03-04 | — | — | CN | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| CN-100457111-C | Use of staurosporine derivatives for the preparation of a medicament | NOVARTIS AG (CH) | 2009-02-04 | — | — | CN | disclosed |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| CN-100443472-C | 3-alkylidenehydrazino substituted heteroaryl compound and medicine containing the same | NISSAN CHEMICAL IND LTD (JP) | 2008-12-17 | — | — | CN | disclosed |
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | disclosed |
| US-20080280880-A1 | Staurosporine Derivatives for Use in Alveolar Rhabdomyosarcoma | UNIVERSITAET ZUERICH (CH) | 2008-11-13 | — | — | US | disclosed |
| EP-1658274-A4 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-11-12 | — | — | EP | disclosed |
| CN-101304749-A | Compositions and methods for less immunogenic pr0tein-lip1d complexes | RES FOUNDATION OF STATE OF UNI (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080207496-A1 | ORGANIC COMPOUND | SI MING-SING | 2008-08-28 | — | — | US | disclosed |
| EP-1951255-A1 | STAUROSPORINE DERIVATIVES FOR USE IN ALVEOLAR RHABDOMYOSARCOMA | Universität Zürich (CH) | 2008-08-06 | — | — | EP | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| CN-101223154-A | Thiophene compounds and thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2008-07-16 | — | — | CN | disclosed |
| CN-100398522-C | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-07-02 | — | — | CN | disclosed |
| WO-2008070739-A1 | KSP ACTIVATORS | CYTOKINETICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008063572-A2 | METHOD FOR STORING HYDROGEN USING NOVEL CARBON-BASED HIGH CAPACITY STORAGE MATERIALS | ALGODIGN, LLC (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| CN-101164539-A | New use of staurosporine derivatives | NOVARTIS AG (CH) | 2008-04-23 | — | — | CN | disclosed |
| WO-2008043811-A1 | STAUROSPORINE DERIVATIVES AND RADIATION | NOVARTIS AG (CH) | 2008-04-17 | — | — | WO | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| CN-100379410-C | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2008-04-09 | — | — | CN | disclosed |
| EP-1904472-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| CN-100370975-C | Inflammatory cytokine production dissociation inhibitor | INST OF MEDICINE MOLECULAR DES (JP) | 2008-02-27 | — | — | CN | disclosed |
| CN-101125138-A | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2008-02-20 | — | — | CN | disclosed |
| CN-101123960-A | Use of staurosporine derivatives for the treatment of multiple myeloma | BRIGHAM & WOMENS HOSPITAL (US) | 2008-02-13 | — | — | CN | disclosed |
| US-20080027060-A1 | DIPEPTIDE NITRILES | ALTMANN EVA | 2008-01-31 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | LIU HONG | 2008-01-24 | — | — | US | disclosed |
| CN-101103977-A | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-16 | — | — | CN | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | disclosed |
| WO-2007147613-A2 | COMBINATIONS COMPRISING STAUROSPRORINES | NOVARTIS AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070299049-A1 | Pharmaceutical Uses of Staurosporine Derivatives | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-12-27 | — | — | US | disclosed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7307095-B2 | Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide | IRM LLC (BM) | 2007-12-11 | — | — | US | disclosed |
| US-7297714-B2 | Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid | IRM LLC (BM) | 2007-11-20 | — | — | US | disclosed |
| US-20070259873-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-11-08 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070232521-A1 | Fluoride carrier for positron emission tomography | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1824477-A1 | USE OF STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA | Novartis AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070191338-A1 | Combinations comprising staurosporines | ATADJA PETER W | 2007-08-16 | — | — | US | disclosed |
| US-7256207-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2007-08-14 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1658267-A4 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007081530-A2 | ENDOLUMINAL MEDICAL DEVICE FOR LOCAL DELIVERY OF CATHEPSIN INHIBITORS | MED INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1565443-A4 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| CN-1980910-A | Benzopyran compound for treating arrhythmia | NISSAN CHEMICAL IND LTD (JP) | 2007-06-13 | — | — | CN | disclosed |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-05-31 | — | — | US | disclosed |
| WO-2007054579-A1 | STAUROSPORINE DERIVATIVES FOR USE IN ALVEOLAR RHABDOMYOSARCOMA | Universität Zürich (CH) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054717-A2 | STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF LEUKEMIA CHARACTERISED BY A SPTBNl -FLT3 MUTATION | UNIVERSITY OF SOUTHAMPTON (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| CN-1934116-A | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070059792-A1 | convergent assembly of a plurality of pairs of oligopeptides; stable C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester; allows a single precursor to participate in a succession of chemical ligation reactions | ASTRAZENECA PHARMACEUTICALS LP | 2007-03-15 | — | — | US | disclosed |
| EP-1751091-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | Elan Pharmaceuticals, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | disclosed |
| WO-2007010954-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-01-25 | — | — | WO | disclosed |
| CN-1897931-A | Inhibitors of cathepsin s | IRM LLC (BM) | 2007-01-17 | — | — | CN | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| CN-1871216-A | Inhibitors of cathepsin s | IRM LLC (BM) | 2006-11-29 | — | — | CN | disclosed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | disclosed |
| EP-1718629-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR THE TREATMENT OF ARRHYTMIA | Nissan Chemical Industries, Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060235220-A1 | Dipeptide nitriles | MISSBACH MARTIN | 2006-10-19 | — | — | US | disclosed |
| US-20060229290-A1 | Staurosporine derivatives for hypereosinophilic syndrome | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-10-12 | — | — | US | disclosed |
| CN-1279036-C | Substituted benzopyran derivatives aganst arrhythmia | NISSAN CHEMICAL IND LTD (JP) | 2006-10-11 | — | — | CN | disclosed |
| CN-1835927-A | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-20 | — | — | CN | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| CN-1832747-A | Combinations comprising staurosporines | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | disclosed |
| CN-1273444-C | Dipeptide nitriles | NOVARTIS AG (CH) | 2006-09-06 | — | — | CN | disclosed |
| US-7091346-B1 | Purine derivatives and processes for their preparation | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| EP-1441737-B1 | STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| CN-1816333-A | Staurosporine derivatives for hypereosinophilic syndrome | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| CN-1264817-C | Certain cyclic thio substitued acylaminoacid amide derivatives | NOVARTIS AG (CH) | 2006-07-19 | — | — | CN | disclosed |
| CN-1805749-A | New pharmaceutical use of staurosporine derivatives | NOVARTIS AG (CH) | 2006-07-19 | — | — | CN | disclosed |
| EP-1677782-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-07-12 | — | — | EP | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006061199-A1 | USE OF STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA | THE BRIGHAM AND WOMEN'S HOSPITAL (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1658267-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| EP-1658274-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1653973-A1 | COMBINATIONS COMPRISING STAUROSPORINES | Novartis AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-7041700-B2 | Substituted benzopyran derivatives against arrhythmia | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-05-09 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060089395-A1 | Nf-kb activation inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| US-20060069140-A1 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1638574-A2 | NEW PHARMACEUTICAL USES OF STAUROSPORINE DERIVATIVES | Novartis AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| EP-1635819-A1 | STAUROSPORINE DERIVATIVES FOR HYPEREOSINOPHILIC SYNDROME | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006021456-A1 | COMBINATION COMPRISING A STAUROSPORINE AND A CYP3A4 INHIBITOR | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050267199-A1 | 2-Amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| EP-1212314-B1 | BENZOPYRAN DERIVATIVE | NISSAN CHEMICAL IND LTD (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20050232915-A1 | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | NAKAJIMA MOTOWO | 2005-10-20 | — | — | US | disclosed |
| WO-2005095326-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1283825-B1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | disclosed |
| EP-1565443-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| CN-1658849-A | Inhibitors of AP-1 and NFAT activation | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658858-A | Remedies for neurodegenerative diseases | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658856-A | Cancer therapeutic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658855-A | O-substituted hydroxyaryl derivatives | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658857-A | NF-kB activation inhibitor | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658872-A | Antiallergic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658850-A | Therapeutic agent for diabetes | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658854-A | Immune related protein kinase inhibitors | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1215055-C | Arylsulfonylamino-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| US-20050159404-A1 | Organic compound | SI MING-SING (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1549618-A1 | PYRAZOLONE COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-20050130959-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-06-16 | — | — | US | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | disclosed |
| US-20050107368-A1 | Selective in presence of at least one other cathepsin isozyme; such as 1-(5,6-dichloro-benzimidazol-1-ylmethyl)-3,3-dimethyl-butyl [2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-hydroxymethyl-ethyl]carbamate | IRM LLC (BM) | 2005-05-19 | — | — | US | disclosed |
| EP-1529056-A2 | POST-CLEAVAGE SULFUR DEPROTECTION FOR CONVERGENT PROTEIN SYNTHESIS BY CHEMICAL LIGATION | Geneprot, Inc. (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005039496-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005034848-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | disclosed |
| WO-2005018568-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-03-03 | — | — | WO | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| WO-2005014004-A1 | COMBINATIONS COMPRISING STAUROSPORINES | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| CN-1582150-A | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG (CH) | 2005-02-16 | — | — | CN | disclosed |
| US-20050020570-A1 | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity | NOVARTIS PHARMACEUTICALS CORPORATION | 2005-01-27 | — | — | US | disclosed |
| CN-1183133-C | 2-amino-6-anilino-purines and their use as medicaments | ��˹��ŵ�� | 2005-01-05 | — | — | CN | disclosed |
| WO-2004112709-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004112794-A2 | NEW PHARMACEUTICAL USES OF STAUROSPORINE DERIVATIVES | NOVARTIS AG (CH) | 2004-12-29 | — | — | WO | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108132-A1 | STAUROSPORINE DERIVATIVES FOR HYPEREOSINOPHILIC SYNDROME | NOVARTIS AG (CH) | 2004-12-16 | — | — | WO | disclosed |
| EP-1485131-A1 | MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | FUJIMOTO ROGER AKI (US) | 2004-11-25 | — | — | US | disclosed |
| US-6812237-B2 | (ARYLAMINOACEAMIDO)ACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-11-02 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| CN-1167697-C | Benzopyran derivatives | �ղ���ѧ��ҵ��ʽ���� | 2004-09-22 | — | — | CN | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| CN-1520406-A | Antiarrhythmic substituted benzopyran derivatives | �ղ���ѧ��ҵ��ʽ���� | 2004-08-11 | — | — | CN | disclosed |
| US-20040152763-A1 | Substituted benzopyran derivatives against arrhythmia | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1441737-A1 | STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY | Novartis AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | disclosed |
| US-20040110806-A1 | Dipeptide derivatives | ALTMANN EVA (CH) | 2004-06-10 | — | — | US | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004033433-A1 | PYRAZOLONE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-22 | — | — | WO | disclosed |
| CN-1489458-A | Inflammatory cytokine production dissociation inhibitor | ��ʽ����ҽҩ��������о��� | 2004-04-14 | — | — | CN | disclosed |
| EP-1401823-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES AGAINST ARRHYTHMIA | Nissan Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004024081-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| US-6677371-B1 | ANTIARRHYTHMIA AGENTS SUCH AS 6-ACETYLAMINO-3,4-DIHYDRO-2,2-DIMETHYL-4-(2-PHENYLETHOXY)-2H-1-BENZOPYRAN-3 -OL, USED FOR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| EP-1373262-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003106615-A2 | POST-CLEAVAGE SULFUR DEPROTECTION FOR CONVERGENT PROTEIN SYNTHESIS BY CHEMICAL LIGATION | GENEPROT, INC. (CH) | 2003-12-24 | — | — | WO | disclosed |
| EP-1355907-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | HO WEN-BIN (US) | 2003-10-09 | — | — | US | disclosed |
| WO-2003075959-A1 | MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| US-6589983-B1 | Antiarrhythmic agents having the prolongation effect on the functional refractory period as a main function | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-08 | — | — | US | disclosed |
| EP-0966439-B1 | CERTAIN CYCLIC THIO SUBSTITUTED ACYLAMINOACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1154992-A4 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN INC (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003037347-A1 | STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY | NOVARTIS AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-0811629-B1 | OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX | NISSAN CHEMICAL IND LTD (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-6555574-B1 | Antiarrhythmic agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| EP-1283825-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | Novartis AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| US-6506936-B1 | Treating fibrotic disorder selected from hepatic cirrhosis and arthritis; inhibiting matrix metalloproteases | FIBROGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| WO-2003000675-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES AGAINST ARRHYTHMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-03 | — | — | WO | disclosed |
| CN-1374957-A | Benzopyran derivative | NISSAN CHEMICAL IND LTD (JP) | 2002-10-16 | — | — | CN | disclosed |
| WO-2002072577-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS. | NOVARTIS AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| CN-1368958-A | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-09-11 | — | — | CN | disclosed |
| WO-2002060898-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1218367-A1 | 4-OXYBENZOPYRAN DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1214307-A1 | 4-OXYBENZOPYRAN DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2002-06-19 | — | — | EP | disclosed |
| EP-1212314-A1 | BENZOPYRAN DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | disclosed |
| CN-1348441-A | N-substituted arylsulfonylamino hydroxamic acids | FIBROGEN INC (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1340054-A | 2-amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-03-13 | — | — | CN | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| WO-2001087828-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2001-11-22 | — | — | WO | disclosed |
| EP-1154992-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| US-6248918-B1 | BIS(DIHYDROCARBYLPHOSPHINOYLALKYL)-1,1'-BINAPHTHOL) AND RARE EARTH OR GROUP 3A METAL SALTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| CN-1066625-C | Therapeutic use of benzopyran derivatives | SMITHKLINE BEECHAM PLC (GB) | 2001-06-06 | — | — | CN | disclosed |
| CN-1066147-C | Purine derivatives and process for preparing same | 诺瓦提斯公司 | 2001-05-23 | — | — | CN | disclosed |
| WO-2001025224-A1 | 4-OXYBENZOPYRAN DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001021609-A1 | 4-OXYBENZOPYRAN DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021610-A1 | BENZOPYRAN DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
| US-6201133-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS, TREATING TNF ALPHA AND MATRIX METALLOPROTEINASE DEPENDENT DISEASES OR CONDITIONS, CANCER | NOVARTIS AG (CH) | 2001-03-13 | — | — | US | disclosed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
| CN-1278244-A | Dipeptide nitriles | NOVARTIS AG (CH) | 2000-12-27 | — | — | CN | disclosed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | disclosed |
| CN-1270169-A | Benzopyrane derivatives and preparation thereof | SMITHKLINE BEECHAM PLC (GB) | 2000-10-18 | — | — | CN | disclosed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000050390-A1 | N-SUBSTITUTED ARYLSULFONYLAMINO HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF C-PROTEINASE AND FOR TREATING OR PREVENTING DISORDERS RELATED TO UNREGULATED COLLAGEN PRODUCTION | FIBROGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000048993-A1 | ARYLAMINOALKYLAMIDES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| CN-1251092-A | Certain cyclic thio substitued acylaminoacid amide derivatives | NOVARTIS AG (CH) | 2000-04-19 | — | — | CN | disclosed |
| US-6034136-A | METALLOPROTEINASE INHIBITOR | NOVARTIS AG (CH) | 2000-03-07 | — | — | US | disclosed |
| EP-0966439-A1 | CERTAIN CYCLIC THIO SUBSTITUTED ACYLAMINOACID AMIDE DERIVATIVES | Novartis AG (CH) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999065881-A1 | HETEROCYCLIC COMPOUNDS AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-23 | — | — | WO | disclosed |
| US-5955481-A | Pyridine type thiazolidines | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| CN-1227099-A | Novel treatment agent | SMITHKLINE BEECHAM PLC (GB) | 1999-09-01 | — | — | CN | disclosed |
| CN-1044605-C | Benzopyran and oxazine derivative | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-08-11 | — | — | CN | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
| US-5880301-A | CATALYSTS FOR PREPARATION OF OPTICALLY ACTIVE BETA-HYDROXYKETONES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-09 | — | — | US | disclosed |
| WO-1999006392-A1 | METHOD FOR PREPARING 2H-1 BENZOPYRANES AND SYNTHESIS INTERMEDIATES | RHODIA CHIMIE (FR) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999002532-A2 | PARTIALLY HYDROGENATED POLYCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | disclosed |
| CN-1202896-A | Purine derivatives and processes for their preparation | 诺瓦提斯公司 | 1998-12-23 | — | — | CN | disclosed |
| US-5846991-A | Pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| US-5840909-A | Pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| EP-0873312-A1 | ALPHA-SUBSTITUTED ARYLSULPHONAMIDO HYDROXAMIC ACIDS AS TNF-ALPHA AND MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| US-5817828-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| US-5817822-A | ANTITUOR, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | NOVARTIS CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| WO-1998042662-A1 | CERTAIN CYCLIC THIO SUBSTITUTED ACYLAMINOACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998041518-A1 | METHOD FOR PREPARING 2H-1 BENZOPYRANES | RHODIA CHIMIE (FR) | 1998-09-24 | — | — | WO | disclosed |
| US-5770624-A | INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA AND MATRIX DEGRADING METALLOPROTEINEASE ACTIVITY | NOVARTIS CORP. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5721264-A | EXHIBIT ANTAGONISTIC EFFECT AGAINST ANGIOTENSIN II; USEFUL FOR PREVENTION AND REMEDY OF HYPERTENSION, CONGESTIVE HEARTFAILURE, CHRONIC RENAL INSUFFICIENCY, ALDOSTERONISM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| EP-0811629-A1 | OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-12-10 | — | — | EP | disclosed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997022587-A1 | ALPHA-SUBSTITUTED ARYLSULPHONAMIDO HYDROXAMIC ACIDS AS TNF-ALPHA AND MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | disclosed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| EP-0763042-A1 | POLYCYCLIC LACTAM DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOUR AGENTS | Novartis AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| EP-0763041-A1 | INDOLOCARBAZOLE DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOR AGENTS | Novartis AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| CN-1144526-A | Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents | NISSAN CHEMICAL IND LTD (JP) | 1997-03-05 | — | — | CN | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| WO-1997005141-A1 | STAUROSPORINE ANALOGUES | NOVARTIS AG (CH) | 1997-02-13 | — | — | WO | disclosed |
| WO-1997005140-A1 | TRINDENE COMPOUNDS | NOVARTIS AG (CH) | 1997-02-13 | — | — | WO | disclosed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |
| WO-1996011196-A1 | PYRAZOLYLMETHYL-THIAZOLIDINES USEFUL AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| CN-1120837-A | Pyrazole derivatives | NISSAN CHEMICAL IND LTD (JP) | 1996-04-17 | — | — | CN | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0693480-A1 | PYRAZOLE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-01-24 | — | — | EP | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995032976-A1 | POLYCYCLIC LACTAM DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOUR AGENTS | CIBA-GEIGY AG (CH) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995032975-A1 | INDOLOCARBAZOLE DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOR AGENTS | CIBA-GEIGY AG (CH) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
| CN-1094613-A | Novel therapeutic agents | SMITHKLINE BEECHAM PLC (GB) | 1994-11-09 | — | — | CN | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
| CN-1086817-A | Chromene and benzo-oxazine derivative | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1994-05-18 | — | — | CN | disclosed |
| US-5280009-A | Herbicide | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-18 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
| EP-0523533-A1 | Substituted pyrimidin derivatives and their use for combatting the growth of undesirable plants | BASF Aktiengesellschaft (DE) | 1993-01-20 | — | — | EP | disclosed |
| US-5093330-A | Selective inhibitors of proteinkinase c | CIBA-GEIGY CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| US-4937246-A | ABSORBED EASILY FROM INTESTINES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0369810-A2 | PAF antagonists as anti-hyperendothelinemia agents | Takeda Chemical Industries, Ltd. (JP) | 1990-05-23 | — | — | EP | disclosed |
| EP-0368670-A1 | Trisubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
| EP-0318235-A2 | PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1989-05-31 | — | — | EP | disclosed |
| EP-0090733-B1 | DISUBSTITUTED POLYMETHYLENE IMINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR (FR) | 1985-10-30 | — | — | EP | disclosed |
| EP-0090733-A1 | Disubstituted polymethylene imines, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1983-10-05 | — | — | EP | disclosed |
| US-4404274-A | Photographic light sensitive element containing yellow color coupler and method for forming yellow photographic images | FUJI PHOTO FILM CO., LTD. (JP) | 1983-09-13 | — | — | US | disclosed |
| US-4269936-A | A COUPLER BASED ON AN ACYLACETAMIDE HAVING BONDED ONTO THE ALPHA CARBON A NITROGEN ATOM ACTIVATED BY TWO CARBONYL GROUPS; SILVER HALIIDE EMULSIONS; AMINE DEVELOPERS; SHARPNESS | FUJI PHOTO FILM CO., LTD. (JP) | 1981-05-26 | — | — | US | disclosed |
| US-4106942-A | COMPOUNDS CONTAINING SULFIDE, KETONE, AND AMIDE GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 1978-08-15 | — | — | US | disclosed |
| US-4022620-A | SILVER HALIDE, AMINE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-05-10 | — | — | US | disclosed |
| US-4012259-A | DICARBONYL METHYLENE GROUP ON A 2,5-DIOXO-1-IMIDAZOLIDINE IS A YELLOW COUPLER | FUJI PHOTO FILM CO., LTD. (JA) | 1977-03-15 | — | — | US | disclosed |
| US-3990896-A | YELLOW COLOR FORMING COUPLERS WITH 5-ALKYLIDINE-3-HYDANTOINYL GROUPS | FUJI PHOTO FILM CO., LTD. (JA) | 1976-11-09 | — | — | US | disclosed |
| US-3990896-A | YELLOW COLOR FORMING COUPLERS WITH 5-ALKYLIDINE-3-HYDANTOINYL GROUPS | FUJI PHOTO FILM CO., LTD. (JA) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200388879-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FUNCTIONALIZED LINEAR SULFONATE ESTER DERIVATIVE COMPOUND CONTAINING ELECTROLYTE ADDITIVES | SELENOI, SELE, SORD | MAOA 4675/4885MAOB 4649/4885 |
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | MAOA 2017/4885MAOB 1658/4885 |
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | MAOA 1469/4885MAOB 1209/4885 |
| US-20180334496-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | CFD, CFH, CFB | MAOA 1923/4885MAOB 1752/4885 |
| US-20100120869-A1 | COMPOUNDS AND METHODS FOR PKC THETA INHIBITION | PRKCQ, PRKCH, PRKCZ | MAOA 3773/4885MAOB 3010/4885 |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | MAOA 1560/4885MAOB 1486/4885 |
| US-20230180756-A1 | TRIAZINE AND PYRIMIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | TPMT, TYMP, TPI1 | MAOA 1773/4885MAOB 1300/4885 |
| US-20130245327-A1 | CARBON NANOHOOPS AND METHODS OF MAKING | CYCS, CDC42, NCDN | MAOA 3661/4885MAOB 4138/4885 |
| US-20180244762-A1 | DUAL PDGF/VEGF ANTAGONISTS | PDGFA, PDGFRA, VEGFA | MAOA 571/4885MAOB 2299/4885 |
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | CXCR1, PTGS1, P2RY1 | MAOA 3225/4885MAOB 3059/4885 |
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | MAOA 1496/4885MAOB 1172/4885 |
| US-20100092559-A1 | BOLDINE COMPOUNDS FOR PROMOTING BONE GROWTH | BMP2, BMP1, FGF23 | MAOA 1779/4885MAOB 979/4885 |
| US-20230201358-A1 | LINKER COMPOUNDS | DCLRE1B, DNASE1L3, DNASE1 | MAOA 2268/4885MAOB 2158/4885 |
| US-20100074939-A1 | HARMINE COMPOUNDS FOR PROMOTING BONE GROWTH | TPH1, TPH2, NGF | MAOA 27/4885MAOB 18/4885 |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | MAOA 3792/4885MAOB 4107/4885 |
| US-20170190766-A1 | ANTIBODIES AND CONJUGATES THEREOF | VEGFA, FLT1, HDGF | MAOA 1086/4885MAOB 3894/4885 |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | MAOA 3792/4885MAOB 4107/4885 |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | MAOA 431/4885MAOB 658/4885 |
| US-10710967-B2 | Pyrimidine derivative | CXCR1, PTGS1, P2RY1 | MAOA 3225/4885MAOB 3059/4885 |
| US-20230382983-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | CFD, CFH, CFB | MAOA 1923/4885MAOB 1752/4885 |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | MAOA 89/4885MAOB 157/4885 |
| US-20150119576-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | ADH1C, ADH1A, CYP2E1 | MAOA 775/4885MAOB 837/4885 |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | MAOA 800/4885MAOB 1342/4885 |
| US-20210154332-A1 | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands | KLK3, CD74, SDCBP | MAOA 4550/4885MAOB 4423/4885 |
| US-20100137612-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND FOR PRODUCTION OF 2- PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZLINE COMPOUND | ADH1C, CYP2E1, ADH1A | MAOA 430/4885MAOB 583/4885 |
| US-20040110806-A1 | Dipeptide derivatives | CTSL, CTSZ, CTSS | MAOA 4103/4885MAOB 2700/4885 |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | MAOA 1498/4885MAOB 1230/4885 |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | MAOA 214/4885MAOB 459/4885 |
| US-20230173081-A1 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | F8, F9, F13A1 | MAOA 2649/4885MAOB 2789/4885 |
| US-20210184258-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING DIHYDROFURANONE BASED COMPOUND | SORD, SDHA, SIK1 | MAOA 3907/4885MAOB 3499/4885 |
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | ITGB4, ITGA4, ITGB1 | MAOA 4832/4885MAOB 4759/4885 |
| US-20080280880-A1 | Staurosporine Derivatives for Use in Alveolar Rhabdomyosarcoma | PAXBP1, PAX3, EWSR1 | MAOA 4874/4885MAOB 4863/4885 |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | MAOA 2766/4885MAOB 1360/4885 |
| US-20090118500-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | MAOA 2523/4885MAOB 2282/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | MAOA 1615/4885MAOB 1389/4885 |
| US-20230203036-A1 | PYRROLO - DIPYRIDINE COMPOUNDS | IMPDH1, DPYD, IGFBP5 | MAOA 4658/4885MAOB 3461/4885 |
| US-20130034517-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | PHOSPHO1, EPHA2, PCTP | MAOA 4615/4885MAOB 4578/4885 |
| US-20110092496-A1 | THIOPHENE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | TEK, MPL, THPO | MAOA 2523/4885MAOB 2282/4885 |
| US-20200055853-A1 | PYRROLO - DIPYRIDINE COMPOUNDS | IMPDH1, DPYD, IGFBP5 | MAOA 4658/4885MAOB 3461/4885 |
| US-20130096095-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | AR, NR5A1, CYP17A1 | MAOA 2991/4885MAOB 2671/4885 |
| US-20070191338-A1 | Combinations comprising staurosporines | MCL1, FLT3, FLI1 | MAOA 1868/4885MAOB 2556/4885 |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | MAOA 247/4885MAOB 399/4885 |
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | SOST, CA1, DUOX2 | MAOA 2528/4885MAOB 2906/4885 |
| US-20030191309-A1 | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production | MMP1, MMP13, COL14A1 | MAOA 479/4885MAOB 608/4885 |
| US-20200054645-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | GLS, AFF1, SLC5A1 | MAOA 3861/4885MAOB 2888/4885 |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | CTSS, CTSV, CTSF | MAOA 1393/4885MAOB 892/4885 |
| US-20130079293-A1 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS | GRIN2B, GRM7, GRM2 | MAOA 3434/4885MAOB 2524/4885 |
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | MAOA 1496/4885MAOB 1172/4885 |
| US-10363290-B2 | Butyrylcholinesterase zwitterionic polymer conjugates | BCHE, ACHE, FCER2 | MAOA 600/4885MAOB 911/4885 |
| US-20090297606-A1 | GAMMA-LACTAM COMPOUNDS FOR PROMOTING BONE GROWTH | NR4A3, BMP4, NR4A1 | MAOA 3260/4885MAOB 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.